Navigation Links
Liver cells benefit from mesenchymal stem cell co-culture prior to transplantation
Date:12/18/2013

Putnam Valley, NY. (Dec. 18, 2013) Hepatocyte (liver cell) transplantation is becoming an accepted therapy for acute liver failure, either for liver regeneration or as a bridge to liver transplantation. However, maintaining the viability and functional aspects of hepatocytes has been a concern even with successful freezing (cryopreservation). In an effort to improve both the viability and function of cryopreserved hepatocytes prior to transplantation, researchers at Kings College Hospital, London, have co-cultured hepatocytes along with human mesenchymal stem cells (MSCs) derived from umbilical cord or fat tissues and found that the co-culturing confers improved hepatocyte survival and function.

The study will be published in a future issue of Cell Transplantation but is currently freely available on-line as an unedited early e-pub at: http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-ct1038fitzpatrick.

The researchers hypothesized that when co-cultured with hepatocytes, MSCs - multipotent connective tissue cells that can differentiate into many kinds of cells - would lend pro-regenerative characteristics to hepatocytes.

"Both human umbilical cord and adipose tissue sources for MSCs were compared," said study corresponding author Dr. Emer Fitzpatrick of King's College Hospital. "Previous studies had used nonhuman cells with limited success. Human MSCs from both umbilical cords and adipose tissue have anti-apoptotic (anti-programmed cell death) and pro-regenerative effects on kidney failure and stroke and they are known to modulate liver injury and promote liver regeneration. While cryopreservation can have deleterious effects on hepatocyte cell engraftment, we wanted to investigate whether a co-culture of human MSCs and hepatocytes would improve hepatocyte function."

They found that MSCs and hepatocytes cultured together demonstrated an improved production of albumin from day five to day 25 of the culture.

The effect, they said, was most prominent at day 15 when albumin production was ten times that of a control monoculture. Urea production also improved in co-culture from day five to day 25. Once more, the viability of the co-cultured hepatocytes was superior to that of monocultured cells, with up to 16 percent improvement.

The researchers noted that MSCs are known to provide structural support for cells in the body and have anti-apoptotic and immunomodulatory effects and that the supportive role of MSCs is "particularly promising in the context of cell transplantation, allowing for sufficient time for an organ for transplant to become available."

"Our results suggest that the presence of the hepatocytes is necessary to stimulate the MSCs to secrete pro-survival factors," concluded the researchers. "The combination of transplanted hepatocytes and MSCs has great promise in the therapy of acute liver failure." "Mechanisms to stabilize hepatocyte cultures prior to transplantation for the treatment of liver diseases are a potentially important step in maximizing the potential of hepatocytes as a therapy" said Dr. Stephen Strom of the Karolinska Institute, Sweden and section editor for Cell Transplantation. "The use of human-derived stem cells as a support mechanism in culture is therefore of interest and further study will illuminate whether the pro-survival factors could be used alone or whether the cells themselves are required".


'/>"/>

Contact: Robert Miranda
cogcomm@aol.com
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Related biology news :

1. Nanotherapy: Treating deadly brain tumors by delivering big radiation with tiny tools
2. Crestor Delivers Latest LDL-C Targets in High-Risk Patients at Lower Doses than Other Statins
3. Researchers unravel genetic mechanism of fatty liver disease in obese children
4. Commonly used diabetes drug may help to prevent primary liver cancer
5. Ben-Gurion U. licenses drug delivery platform for central nervous system diseases to NY biotech firm
6. Gut microbiota transplantation may prevent development of diabetes and fatty liver disease
7. Gallbladder shown as potential stem cell source for regenerative liver and metabolic disease
8. Family history of liver cancer increases risk of developing the disease
9. Modest alcohol intake associated with less inflammation in patients with common liver disease
10. Delivery of gene-therapy for heart disease boosted 100-fold; now in 100-patient trial
11. Cancerous tumors deliver pro-metastatic information in secreted vesicles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2016)... According to the new market research report "Biometric System Market ... Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, and Region ... to grow from USD 10.74 Billion in 2015 to reach USD 32.73 ... Continue Reading ... ...
(Date:11/17/2016)... 17, 2016 Global Market Watch: Primarily ... Banks, Population-Based Banks and Academics) market is to witness a ... Biobanks shows the highest Compounded Annual Growth Rate (CAGR) of ... during the analysis period 2014-2020. North America ... followed by Europe at 9.56% respectively. ...
(Date:11/15/2016)... Nov 15, 2016 Research and Markets has ... to 2021" report to their offering. ... ... Billion by 2021 from USD 6.21 Billion in 2016, growing at ... Growth of the bioinformatics market is driven by the growing demand ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... ... December 01, 2016 , ... The Conference Forum has announced that the ... will take place on February 1-3, 2017 at the Roosevelt Hotel in New York ... program provides a unique 360-degree approach, which addresses the most up-to-date information regarding business ...
(Date:12/2/2016)...   SurePure, Inc. (OTCQB: SURP) a global ... has concluded an agreement with Tamarack Biotics under which ... to acquire units of the Company,s patented photopurification technology ... Concurrently with the option, SurePure has ... will seek regulatory approvals in the United ...
(Date:11/30/2016)... 30, 2016 The global Pyrogen ... hold a dominant share in the overall market. The ... Inc., and Merck KGaA, held a lion,s share of ... Research observes that these companies are expected to retain ... that are do not require rabbit pyrogen testing along ...
(Date:11/30/2016)... CHICAGO , Nov. 30, 2016  Tempus, ... customized cancer care, and Penn,s Abramson Cancer Center ... have a positive response to immunotherapy treatment based ... As part of a research collaboration, ... pancreatic and melanoma cancer patient data to Penn. ...
Breaking Biology Technology: